Relying on J&J’s analyses to assess vaccine booster dose data -U.S. FDA staff

Published by

(Reuters) – U.S. Food and Drug Administration scientists said on Wednesday they did not have time to analyze data submitted by Johnson & Johnson on a booster dose of its single-dose COVID-19 vaccine, in a rare case where the agency relied on a company’s analyses to brief its advisory panel. An outside panel of experts will meet on Friday to discuss whether a booster dose of J&J’s vaccine is safe and effective anywhere between two months and six months after taking the original dose. (Reporting by Manas Mishra in Bengaluru; Editing by Anil D’Silva)

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *